Drugs / JY025
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04874844 | Jul 2021 → Mar 2022 | non-small cell lung carcinoma | Beijing Dongfang Biotech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JY025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04874844 ↗ |
| Action | Inhibit | “anti-VEGFR2” NCT04874844 ↗ |
| Modality | Monoclonal antibody | “fully human monoclonal antibody” NCT04874844 ↗ |